Headlines

Japan Approves BridgeBio Pharma-AstraZeneca Partnered Rare Heart Disease Drug

BridgeBio’s acoramidis wins Japan’s approval for ATTR-CM. Phase 3 data show a 42% reduction in key heart-related events. AstraZeneca’s Alexion to market it.

read more

Join the newsletter

Subscribe to get our latest content by email.

    We respect your privacy. Unsubscribe at any time.

    Leave a Reply

    Your email address will not be published. Required fields are marked *